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Neural progenitor cellsFragile X syndrome, one of the most common forms of inherited mental retardation, is caused by expan-
sion of the CGG repeat in the 50-untranslated region of the X-linked Fmr1 gene, which results in transcrip-
tional silencing and loss of expression of its encoded protein FMRP. The loss of FMRP increases
proliferation and alters fate speciﬁcation in adult neural progenitor cells (aNPCs). However, little is
known about Fmr1 mRNA regulation at the transcriptional and post-transcriptional levels. In the present
study, we report that miR-130b regulated Fmr1 expression by directly targeting its 30-untranslated region
(30 UTR). Up-regulation of miR-130b in mouse embryonic neural progenitor cells (eNPCs) decreased Fmr1
expression, markedly increased eNPC proliferation and altered the differentiation tendency of eNPCs,
suggesting that antagonizing miR-130b may be a new therapeutic entry point for treating Fragile X
syndrome.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Fragile X syndrome, the most common form of inherited mental
retardation, is almost always caused by expansion of the CGG re-
peat in the 50-untranslated region of the X-linked Fragile X Mental
Retardation 1 gene (Fmr1), which results in transcriptional silenc-
ing and loss of expression of its encoded Fragile X Mental Retarda-
tion Protein (FMRP) [1,2]. The CGG triplet region is highly
polymorphic in the population. Normal alleles have between 6
and 54 copies and are stably transmitted to offspring. A pre-muta-
tion allele arises when repeats expand to between 55 and 200 cop-
ies. Pre-mutation alleles are rather unstable and can evolve into a
full mutation during maternal transmission. A full mutation has
over 200 repeats and leads to hypermethylation of the CGG region,
transcriptional silencing and abolished production of FMRP [3].
FMRP is an evolutionarily conserved RNA-binding protein that
is particularly abundant in the brain due to its high expression in
neurons [4–6]. Several studies have shown that FMRP plays a
critical role in regulating mRNA translation, transport and stability
[7–9]. In neurons, FMRP may modulate mRNA expression by
controlling recognition, export, translational efﬁciency and
stability of target mRNAs [9,10]. FMRP silencing abnormallyregulates brain mRNA translation and disrupts the composition
of the appropriate protein milieu, which mediates defects in neuro-
nal development and synaptogenesis [8,11,12]. Deletion of FMRP
from adult neural progenitor cells (aNPCs) leads to reduced
hippocampal neurogenesis both in vitro and in vivo and markedly
impairs hippocampus-dependent learning in mice [13]. Loss of
FMRP increases proliferation and alters fate speciﬁcation in adult
neural progenitor cells. The altered function of adult neural
progenitor cells (aNSCs) is partially dependent on CDK4 and GSK3b
signaling, which are both known FMRP targets of translational
repression [14].
MicroRNAs (miRNAs) are a class of short (22 nucleotide), sin-
gle-stranded non-coding RNAs that usually bind their target
mRNAs through imperfect base pairing in the 30-untranslated re-
gions (30 UTRs) and impact protein expression by translational
repression, mRNA degradation or the promotion of mRNA decay
[15,16]. Cumulating evidence allocates miRNA function to integral
parts of regulatory cellular processes, including cell proliferation
and differentiation, regulation of metabolic activities and tumori-
genesis [17–19]. To date, many miRNAs that are speciﬁcally or
richly expressed in the mammalian brain have been identiﬁed.
For example, miR-9, a brain-speciﬁc miRNA, regulates neural pro-
genitor cells (NSCs) proliferation and differentiation by binding
to the 30 UTR of TLX mRNA [20]. MiR-137 modulates the prolifera-
tion and differentiation of adult NSCs by targeting EZH2, a histone
H3 lysine 27 methyltransferase [21]. Additionally, miR-137 regu-
lates neuronal maturation by inhibiting dendrite formation by
binding Mind bomb 1 (Mibl) [22]. Mibl is an ubiquitin ligase that
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miRNA functions have been revealed, the precise roles of many
miRNAs in the proliferation, differentiation and migration of
embryonic neural progenitor cells (eNPCs) remain largely un-
known. In this study, we show that miR-130b regulates FMRP
translation and therefore modulates mouse eNPCs proliferation
and fate determination. These data suggest that the functional
interaction between miRNA and Fmr1 plays an important modula-
tory role in eNPCs fate determination.2. Materials and methods
2.1. Prediction of microRNAs that target Fmr1 mRNA
The miRNAs targeting Fmr1 mRNA were predicted using three
different prediction programs: PicTar (http://pictar.mdc-ber-
lin.de/cgi-bin/new_PicTar_mouse.cgi), TargetScan Mouse (http://
www.targetscan.org/mmu_61) and miRDB (http://mirdb.org/miR-
DB). Only the miRNAs predicted by all three algorithms were con-
sidered to be putative regulators of Fmr1 and were selected for
further experimental identiﬁcation.
2.2. Cell culture
Human HEK-293T cells were maintained in Dulbecco’s modiﬁed
Eagle medium (DMEM) containing 4500 mg/l glucose, 4 mM L-glu-
tamine, and 10% heat-inactivated fetal bovine serum (Gibco)
without sodium pyruvate at 37 C in a 5% CO2 atmosphere.
Primary embryonic NPCs were isolated from E12.5 fetal mice.
Pregnant mice were treated, anesthetized and euthanized in accor-
dance with institutional guidelines. The fetal mice were quickly re-
moved out of the uterus and put into the cold PBS. After being
washed with cold PBS for 3 times, the brain tissues were chopped
and enzymatically digested by using Papain at 37 C for 20 min.
Dissociated cells were cultured in DMEM-F12 (1:1) medium (Gib-
co, 11320033) supplemented with 10% B27 (Gibco, 0080085-SA),
20 ng/ml epidermal growth factor (EGF, R&D, 2028-EG-200)) and
10 ng/ml basic ﬁbroblast growth factor (bFGF, R&D, 3139-FB-025).
2.3. Construction of plasmid-mFmr1-30 UTR and plasmid-mFmr1-30
UTR containing the miR-130b target site mutant
Mouse genomic DNA was isolated and puriﬁed from eNPCs with
QIAamp DNA Mini Kit according to the manufacturer’s protocol.
The 30-untranslated region (UTR) sequence of Fmr1was PCR ampli-
ﬁed directly from the genomic DNA using the following primers:
50-GATACTCGAGGGCTGCGCACGGGTAAAGA-30 (forward) and 50-
CATGGCGGCCGCTGTAATATGAATCAACTCCAACTC-30 (reverse). The
primers were designed incorporating Xho I and Not I restriction
sites and 4 bp of extra random sequence to aid in restriction diges-
tion. Xho I and Not I-digested PCR products were cloned into a Xho
I- and Not I-digested psiCHECK-2 dual luciferase reporter vector
(Promega, C8021). The recombinant plasmids (psiCHECK2-
mFmr1-30 UTR) were conﬁrmed by sequencing. The miR-130b tar-
get site mutant plasmid was constructed by ShangHai RayGene
Biotechnology Co., Ltd.
2.4. Construction of a lentiviral vector expressing sh-miR-130b
U6-miR130b or U6-control expression constructs were derived
from a previously generated U6-shRNA lentiviral construct
(Lenti-137) by using a PCR-shagging approach as described previ-
ously [23]. A lenti-130b reverse primer (50-TATCGATAAAAAAA-
CAGTGCAATGATGAAAGGGCATTCTCTTGAAATGCCCTTTCATCATTGC
ACTGAAACAAGGCTTTTCTCCAAGGGA-30) and a lenti-control re-verse primer (50-TATCGATAAAAAAAAATTCTCCGAACGTGTCACGTT
CTCTTGAAACGTGACACGTTCGGAGAATTAAACAAGGCTTTTCTCCAA
GGGA-30) were used in combination with a common forward
primer complementary to the 50 end of the U6 promoter (50-
AAAGTTAACTAGTGGATCCGACGCCGCCATCTC-30) to amplify the
entire U6 promoter and shRNA in a single PCR product. Ampliﬁca-
tion was initiated by denaturing at 94 C for 5 min, followed by 30
cycles of 30 s each at 94 C, 30 s at 60 C and 40 s at 72 C, with a
ﬁnal extension step of 5 min at 72 C. The PCR products were
cloned into the TOPO TA vector, and the recombinant constructs
were then veriﬁed by sequencing. U6-miR130b or U6-control
expression constructs were removed from the TOPO vector for
transfer to a lentiviral vector by Hpa I and Cla I restriction diges-
tion. The lentiviral vectors were also veriﬁed by sequencing.2.5. Virus production
The lentiviral vector expressing sh-miR-130b and the packing
vectors pMDL, pRev, and pVSV-G were co-transfected into human
embryonic kidney (HEK) 293T cells, and culture medium was col-
lected at 48, 72 and 96 h. The medium was ﬁltered through 0.22-
lm pore nitrocellulose ﬁlters and then centrifuged in a Beckman
ultracentrifuge (Beckman, Avanti J-301) at 55,000g for 2 h at
16 C. The precipitate was resuspended in NPC complete medium.
The viral supernatant was directly infected into cells or stored at
80 C.2.6. Luciferase reporter assay of candidate miR-130b target Fmr1
Luciferase reporter experiments were performed in the
HEK293T cell line. Cells were plated 1 day before transfection in
a 24-well plate at a density of 2  105 cells/well. Cells were co-
transfected with 1 lg of psiCHECK2-30 UTR plasmid, 1 lg of sh-
miR-130b TOPO (sh-miR-130b cloned into a TOPO vector) or
TOPO-control using the calcium phosphate method. At 48 h after
transfection, the cell extract was obtained, and Fireﬂy and Renilla
luciferase activities were measured with the dual-luciferase repor-
ter system (Promega, E1980) according to the manufacturer’s
instructions. R-Luc activity was normalized to F-Luc activity to ac-
count for variation in transfection efﬁciencies. Luciferase experi-
ments were repeated three times.2.7. Quantitative RT-PCR
Total RNAs were isolated from the viral over-expressing NPCs
using RNAiso (TakaRa, D9108A). RNA samples were reverse tran-
scribed into cDNA with oligo (dT)20 and SuperScript III (Invitrogen,
18080051). Real-time PCR was performed with gene-speciﬁc
primers and Power SYBR Green PCR Master Mix (Applied Biosys-
tems, 4367660) using the 7500 Standard Real-Time PCR System
(Applied Biosystems). GAPDH was used as an endogenous control
for all samples. Primers for qPCRwere as follows. mGAPDH: 50-CCTC
GTCCCGTAGACAAAATG -30 (forward) and 50-TCTCCACTTTGCC
ACTGCAA-30 (reverse); mFMR1: 50-AGGTGCCAGAAGATTTACGACA-
30 (forward) and 50-CTCGCTTTGAGGTGACTTCATT-30 (reverse). All
real-time PCR reactions were performed in triplicate, and RQs were
calculated using the DDCt method with calibration to control
samples.
Mature miR-130b expression was also detected by qPCR reac-
tion. The Bulge-Loop™miRNA qRT-PCR Primer and the U6 negative
control were purchased from Guangzhou RiboBio Co. Ltd. Reverse
transcription and qPCR reactions were performed according to
the manufacturer’s instructions.
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Fig. 1. Identiﬁcation of target sites in the 30 UTR of mouse Fmr1 (mFmr1). (A) Schematic diagram of themFmr1message including mouse miR-130b (mmu-miR-130b) binding
sites in the 30 UTR. (B) miR-130b binding site 1 in the 30 UTR of Fmr1 is highly conserved in mammals. (C) Schematic diagram showing the predicted seed region where miR-
130b is expected to bind the mFmr1 30 UTR (above) and the mutated version (below) lacking the binding site for miR-130b. (D) and (E) HEK-293T cells were transiently co-
transfected with the luciferase reporter vector containing wild-typemFmr1 30 UTR (D) or mutant (E) in the presence of mmu-miR-130b together or shRNA-control. Luciferase
activity was evaluated 24 h after transfection as described in Section 2. These data are a representative of at least three independent experiments.
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Cells were washed twice in ice-cold phosphate-buffered saline
and lysed in RIPA lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl,
1% NP-40, 0.1% SDS) in the presence of protease inhibitors. Protein
concentration was determined using the BCA protein assay (Tian-
Gen, PA115) with bovine serum albumin as the standard, and equal
amounts of protein were analyzed by SDS–polyacrylamide gel
electrophoresis. The proteins were then electroblotted onto a poly-
vinylidene ﬂuoride (PVDF) membrane (Millipore, IPVH00010). For
immunoblot experiments, membranes were blocked in TBS-T con-
taining non-fat 5% dried milk for 1 h and then incubated at 4 C
over night with anti-FMRP primary antibody (Abcam, ab69815).
Anti-GAPDH (Sigma–Aldrich, G8795) was used as an internal load-
ing control. Detection was performed with peroxidase-conjugatedsecondary antibodies using the enhanced chemiluminescence sys-
tem (Thermo, 34094).
2.9. Proliferation and differentiation analyses of cultured eNPCs
To study cell proliferation, we plated eNPCs on 24-well plates
containing glass coverslips coated with poly-L-ornithine and lami-
nin at a density of 50,000 cells/well in proliferation medium
[DMEM-F12 (1:1) medium (Gibco, 11320033) supplemented with
10% B27 (Gibco, 0080085-SA), 20 ng/ml epidermal growth factor
(EGF, R&D, 2028-EG-200), and 10 ng/ml basic ﬁbroblast growth
factor (bFGF, R&D, 3139-FB-025)]. At 20 h post-plating, 5 lM
5-bromo-20-deoxyuridine (BrdU, Sigma–Aldrich) was added to
the culture medium for 2 h. NPCs were ﬁxed with 4% paraformal-
dehyde for 30 min at room temperature and then washed with
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Fig. 2. MiR-130b over-expression suppresses FMRP expression. (A) eNPCs cultured under proliferating conditions expressed the neural progenitor markers Nestin
(cytoplasmic, red) and Sox2 (nuclear, green; DAPI in blue). (B) miR-130b was over-expressed in eNPCs and conﬁrmed by qRT-PCR (⁄⁄⁄P < 0.05). (C) Fmr1 mRNA level was
decreased (⁄⁄⁄P < 0.05) when miR-130b was over-expressed in eNPCs. (D) Western blot shows that over-expression of miR-130b signiﬁcantly reduced Fmr1 expression in
protein levels. (E) Western blot shows that Fmr1 expression was increased in protein levels when endogenous miR-130b was down-regulated by anti-miR-130b in mouse
eNPCs. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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incorporation, ﬁxed cells were pretreated with 1 M HCl for
30 min at 37 C and then washed with borate buffer, pH 8.5, for
30 min. For the differentiation assay at 24 h post-plating, cells
were changed into differentiation medium for 4 days, followed
by ﬁxation with 4% paraformaldehyde for 30 min and then wash-
ing with PBS.
For immunocytochemistry staining, cells were preblocked using
0.1 M TBS containing 5% normal donkey serum and 0.3% Triton X-
100 for 1 h, followed by overnight incubation with primary
antibodies: anti-Brdu (Abcam, ab6326), anti-GFP (Abcam,
ab1218), mouse neuron-speciﬁc type b-III tubulin (Promega,
G712A), or rabbit glial ﬁbrillary acidic protein (DAKO, Z-0334).
After being washed with TBS, the cells were incubated with sec-
ondary antibodies that included Alexa Fluor 594 donkey anti-rat
IgG (H+L) (Invitrogen, A21209) and Alexa Fluor 488 donkey anti-
mouse IgG (H+L) (Invitrogen, A21202), followed by counterstaining
with the ﬂuorescent nuclear dye 40,6-dimidino-20-phenylindoledihydrochloride (DAPI, Sigma–Aldrich, B2261). After the cells were
mounted, the numbers of Tuj1-, GFAP- or BrdU- positive cells were
examined with a conventional ﬂuorescence microscope.
2.10. Statistical analysis
Statistical analysis was performed using ANOVA and Student’s
t-test, unless speciﬁed with the aid of SPSS v.17. All data are shown
as the means with standard error of mean (mean ± SEM). Probabil-
ities of P < 0.05 were considered signiﬁcant.
3. Results
3.1. The 30 UTR of the Fmr1 mRNA is a target of miR-130b
According to the PicTar [24], TargetScan [25], and MiRtarget2
[26] algorithms for microRNA target prediction, several miRNAs
putatively targeted the 30 UTR of Fmr1 mRNA. We focused our
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Fig. 3. Down-regulation of FMRP by miR-130b leads to increased eNPCs proliferation. (A) Immunocytochemistry shows an increased number of BrdU-positive cells in miR-
130b-over-expressing cells. (B) Quantitative analysis shows that a higher percentage of miR-130b eNPCs incorporated BrdU.
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brain and is highly conserved between human and mouse [27].
Comparing the results obtained from different searches, we found
that the 30 UTR of the Fmr1 gene comprises two miR-130b bindingsites (Fig. 1A), and these sites are highly conserved in mouse, rat,
and human (Fig. 1B).
The most direct approach for experimentally validating miRNA
targets is to clone the predicted miRNA-binding sequence
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neurons. (B) Immunocytochemistry shows that miR-130b-over-expressing eNPCs and controls could differentiate into GFAP+ (red) astrocytes. (C) and (D) Quantitative
analyses of differentiated eNPCs demonstrate that miR-130b-over-expressing eNPCs differentiated into fewer Tuj1+ neurons (44.57%) but more GFAP+ astrocytes (23.03%)
compared to the negative control. Statistical analyses were performed using a two-tailed unpaired Student’s t-test. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
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with the miRNA of interest for dual-luciferase assays. Therefore,
we cloned the 30 UTR of mouse Fmr1 into the psiCHECK-2 reporter
vector, expressing both Renilla and Fireﬂy luciferase, at the 30 end of
the Renilla luciferase coding sequence. This reporter vector, to-
gether with miR-130b or negative control miRNA, was transfected
into HEK-293T cells. We found that miR-130b signiﬁcantly reduced
luciferase activity compared to the negative control (Fig. 1C),
which suggests that miR-130b could target the 30 UTR of Fmr1
mRNA and impair its translation. To further conﬁrm this result,
we generated a deleted mutant Fmr1 30 UTR sequence that lacks
the binding site of miR-130b, TTGCACT (Fig. 1D), and used it to re-
place the wild-type Fmr1 30 UTR sequence at the 30 end of the Renil-la luciferase coding sequence in the psiCHECK-2 reporter vector.
We observed that the mutant 30 UTR of Fmr1 increased the relative
luciferase activity by four-fold when compared to the wild-type 30
UTR (Fig. 1E), suggesting that Fmr1 mRNA was an authentic target
of mmu-miR-130b.
3.2. MiR-130b suppresses Fmr1 expression in eNPCs
FMRP was expressed in Sox2 and Nestin double-positive adult
and embryonic neural progenitor cells and in either NeuroD1-posi-
tive or doublecortin (DCX)-positive newly generated neurons [14].
To investigate the effect of miR-130b on Fmr1 expression in mouse
eNPCs, we isolated eNPCs from fetal brains of ICR mice at
X. Gong et al. / Biochemical and Biophysical Research Communications 439 (2013) 493–500 499embryonic day 12.5. Nearly all cultured eNPCs were Sox2 and Nes-
tin double-positive (Fig. 2A), suggesting a relative homogeneity of
these primary eNPCs.We then establishedmiR-130b-over-express-
ing eNPCs using a lentiviral pMDL system and found that miR-130b
expression was upregulated approximately 40-fold compared to
control eNPCs (Fig. 2B). In the miR-130b-over-expressing eNPCs,
both Fmr1 mRNA levels (Fig. 2C) and protein levels (Fig. 2D) were
signiﬁcantly reduced compared to the control. These results sug-
gest that miR-130b could suppress Fmr1 expression in eNPCs.
To further conﬁrm the relationship between endogenous miR-
130b and FMRP expression, we infected anti-miR-130b which
complemented endogenous miR-130b in mouse eNPCs, and found
increased FMRP protein levels in these eNPCs compared with the
negative control (Fig. 2E), suggesting that Fmr1 is regulated by
endogenous miR-130b in eNPCs.
3.3. MiR-130b alters eNPC proliferation
A previous study has shown that FMRP controls proliferation of
adult neural stem cells in mice [14] and neural stem cells and the
germline in Drosophila [28,29]. The loss of mouse FMRP and
Drosophila FMRP led to a signiﬁcant increase in the number of
mitotic NPCs [14,28,29]. Because miR-130b can regulate FMRP
expression, we sought to determine whether miR-130b could have
an impact on eNPC proliferation. To tackle this question, we used
BrdU, a pyrimidine analogue of thymidine that selectively
incorporates into cell DNA at the S phase of the cell cycle, to
pulse-label proliferating cells for 4 h before paraformaldehyde
ﬁxation to assess the proliferation of eNPCs. We found that
miR-130b-over-expressing eNPCs exhibited twice as much BrdU
incorporation as the negative control (Fig. 3A and B).
3.4. MiR-130b alters eNPC fate speciﬁcation
The effect of FMRP on neural differentiation has been previously
studied, and the results were controversial. Fragile X human
embryonic stem cells (FX-hESCs) showed abnormal neurogenesis
during neural differentiation, leading to poorer neuronal matura-
tion and higher gliogenic development when compared to normal
human embryonic stem cells [30]. Similarly, the loss of FMRP from
mouse adult neural progenitors was shown to generate more glial
cells at the expense of neurons [13,14]. However, it was also
reported that mouse and human FMRP-deﬁcient neurospheres
generated more Tuj1-positive cells than the control neurospheres
generated from normal mouse and human brains [31]. To deter-
mine whether miR-130b could affect neuronal and astrocyte differ-
entiation in eNPCs, we performed spontaneous differentiation by
removing the growth factors. eNPCs with or without exogenous
miR-130b were differentiated for 3 days, and the phenotypes of
differentiated cells were stained using cell lineage-speciﬁc
antibodies: b-III tubulin (Tuj1) for neurons and glial ﬁbrillary acidic
protein (GFAP) for astroglia. The cultured cells were induced to dif-
ferentiate into neurons (Fig. 4A) and astrocytes (Fig. 4B); however,
miR-130b-over-expressing eNPCs exhibited a 44.57% decrease in
neuronal differentiation (Fig. 4C) and a 23.03% increase in astrocyte
differentiation (Fig. 4D) compared to the negative control. This re-
sult was consistent with previous studies [13,14,30] and suggested
that miR-130b alters embryonic neurogenesis by inhibiting FMRP
expression.4. Discussion
Fragile X syndrome is a neurodevelopmental disorder caused by
the selective loss of FMRP production. Recently, an increasing
number of studies showed that NPCs lacking FMRP undergoaberrant neural differentiation that could contribute to the patho-
genesis of fragile X mental retardation. Some experimental evi-
dence has demonstrated that the loss of functional FMRP in
aNPCs leads to reduced neurogenesis both in vitro and in vivo
and markedly impairs hippocampus-dependent learning in mice
[13,14]. Eadie et al. reported that loss of Fmr1 expression can pro-
duce region-speciﬁc alterations in hippocampal adult neurogenesis
and alter anxiety-related behaviors in mice [32]. Moreover, Telias
et al. showed that neural differentiation of fragile X human embry-
onic stem cells reveals abnormal neurogenesis and aberrant gene
expression, leading to poor neuronal maturation and high gliogenic
development [30]. Another study [31] reported that FMRP-deﬁ-
cient NPC cultures from the brains of Fmr1-KO mice and human
fragile X fetuses showed an altered ratio of Tuj1-positive to glial
ﬁbrillary acidic protein (GFAP)-positive cells. Despite the known
relationship between loss of functional FMRP and aberrant neural
differentiation, the consequences of ﬁnely tuned modulation of
Fmr1 expression on NPC neuronal differentiation are still poorly
understood.
To further examine this issue, we down-regulated Fmr1 expres-
sion in mouse eNPCs using microRNA and analyzed fate speciﬁca-
tion. We found that miR-130b, one of the brain-expressed
microRNAs, has two binding sites in the 30 UTR of Fmr1 and can
negatively modulate the expression of Fmr1. Our study has demon-
strated that miR-130b promoted mouse eNPC proliferation,
decreased neuronal differentiation and increased glial differentia-
tion via downregulation of Fmr1 expression, suggesting that the
ﬁnely tuned modulation of Fmr1 expression appears to be crucial
to neurogenesis.
miRNAs are endogenously encoded single-stranded RNAs that
can post-transcriptionally regulate gene expression via either
translational inhibition or mRNA degradation [33]. One mRNA
can be targeted by multiple miRNAs, and therefore, miRNAs often
act as ﬁne-tuning devices rather than primary gene regulators. Pre-
vious studies showed that miR-125b, miR-132, miR-101, miR-129-
5p and miR-221 could target the 30 UTR of Fmr1 mRNA and are in-
volved in the molecular pathology of Fragile X syndrome at the
synaptic structure and function [12,34]. In this study, we found
that miR-130b is an important regulator of Fmr1 and is responsible
for NPC fate determination. Because miR-130b can negatively
modulate the expression of Fmr1, antagonizing miR-130b may
serve as a new therapeutic entry point for treating Fragile X
syndrome.
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